Nuclear recoil effect in targeted alpha therapy - do we need to concern about it?

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21340%2F22%3A00376072" target="_blank" >RIV/68407700:21340/22:00376072 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Nuclear recoil effect in targeted alpha therapy - do we need to concern about it?
Original language description
Exquisite results of some preclinical and clinical trials encourage wider use and further studies of alpha emitters in cancer therapy. However, there is still some controversy about the nuclear recoil effect and the radioactive progeny release from the radiopharmaceutical preparations. This effect not only complicates the determination of radionuclidic and radiochemical purity of the prepared radiopharmaceuticals, but may also negatively affect the treatment outcome due to unwanted irradiation of non-target tissues. While the current clinical trials based on α-emitters, e.g. treatment with 225Ac-labelled PSMA ligands, indicate relatively good short-term tolerability, the long-term studies evaluating the impact of inevitably released radioactive progeny in patients are missing. This talk is thus an attempt to summarize the available literature data of current approaches in targeted alpha particle therapy (TAT) employing low-molecular weight vectors as well as nanomaterials. Strategies on possible elimination of nuclear recoil effect, particularly based on nanomaterials, would be discussed together with an outlook to future possible directions in TAT.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)